Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi; Yamamoto, Wataru; Hashimoto, Motomu; Murata, Koichi; Onishi, Akira; Jinno, Sadao; Hara, Ryota; Son, Yonsu; Amuro, Hideki; Takeuchi, Tohru; Yoshikawa, Ayaka; Katayama, Masaki; Yamamoto, Keiichi; Hirao, Makoto; Okita, Yasutaka; Kumanogoh, Atsushi; Nakata, Ken

doi:https://doi.org/10.1007/s10067-021-05609-7

Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi et al.

Clinical Rheumatology, 2021, 40(7), 2673-2680

Number of Access:2,410（2025-09-03 11:41 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93248

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
ClinRheumatol_40_7_2673	pdf	None	1.26 MB	53	2023.12.07

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
Creator	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, Kosuke
	CreatorName Hirano, Toru
	NRID 1000010815658 1000010815658 CreatorName Maeda, Yuichi
	CreatorName Yamamoto, Wataru
	NRID 1000060512845 1000060512845 CreatorName Hashimoto, Motomu
	NRID 1000060806793 1000060806793 CreatorName Murata, Koichi
	CreatorName Onishi, Akira
	CreatorName Jinno, Sadao
	NRID 1000010597107 1000010597107 CreatorName Hara, Ryota
	CreatorName Son, Yonsu
	CreatorName Amuro, Hideki
	CreatorName Takeuchi, Tohru
	CreatorName Yoshikawa, Ayaka
	CreatorName Katayama, Masaki
	CreatorName Yamamoto, Keiichi
	CreatorName Hirao, Makoto
	CreatorName Okita, Yasutaka
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 CreatorName Kumanogoh, Atsushi
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 CreatorName Nakata, Ken
Subject	ANSWER cohort
	Baricitinib
	Drug retention
	Rheumatoid arthritis
	Sarilumab
	Tofacitinib
Description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s10067-021-05609-7
Description	Ebina K., Hirano T., Maeda Y., et al. Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clinical Rheumatology 40, 2673 (2021)
Abstract	Objectives: The aim of this multicenter, retrospective study was to clarify the retention rates of sarilumab (SAR), baricitinib (BAR), and tofacitinib (TOF) in patients with rheumatoid arthritis (RA). Methods: Patients treated with either SAR (n = 62), BAR (n = 166), or TOF (n = 185) (females, 80.9%; age, 61.0 years; disease duration, 11.1 years; rheumatoid factor positivity, 84.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate, 4.3; concomitant prednisolone dose, 5.3 mg/day [47.0%] and methotrexate dose, 8.8 mg/week [58.4%]; biologics- or Janus kinase inhibitors-switched cases 78.4%) were included. The reasons for drug discontinuation were classified into 4 major categories (lack of effectiveness, toxic adverse events, non-toxic reasons, and remission) by each attending physician. The drug retention rate was estimated at 18 months using the Kaplan–Meier method and adjusted for potential confounders by Cox proportional hazards modeling. Results: The discontinuation rates of SAR, BAR, and TOF for the corresponding reasons were as follows, respectively: lack of effectiveness (15.7%, 15.6%, and 21.5%; P = 0.84), toxic adverse events (15.8%, 12.1%, and 12.3%; P = 0.35), non-toxic reasons (10.9%, 7.7%, and 6.8%; P = 0.35), and remission (0.0%, 2.8%, and 0.0%; P = 1.0). The overall retention rates excluding non-toxic reasons and remission were as follows: 68.8% for SAR, 72.5% for BAR, and 66.7% for TOF (P = 0.54). Conclusions: After adjustment by potent confounders, SAR, BAR, and TOF showed similar discontinuation rates due to lack of effectiveness and toxic adverse events.Key Points• This is the first retrospective multicenter study that aimed to clarify the retention rates and reasons for discontinuation of SAR, BAR, and TOF in patients with RA.
Publisher	Springer Science and Business Media Deutschland GmbH
Source Title	Clinical Rheumatology
Volume (Issue)	40(7)
Page	2673-2680
Date of Issued	2021-07-01
Language	English
Handle URL	https://hdl.handle.net/11094/93248
PISSN	07703198
eISSN	14349949
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1007/s10067-021-05609-7
Access Rights	open access
CopyRight	© 2021, International League of Associations for Rheumatology (ILAR).
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Clinical Rheumatology. 2021, 40(7), p. 2673-2680
DC.title	Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
DC.creator	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Onishi, Akira
	Jinno, Sadao
	Hara, Ryota
	Son, Yonsu
	Amuro, Hideki
	Takeuchi, Tohru
	Yoshikawa, Ayaka
	Katayama, Masaki
	Yamamoto, Keiichi
	Hirao, Makoto
	Okita, Yasutaka
	Kumanogoh, Atsushi
	Nakata, Ken
DC.publisher	Springer Science and Business Media Deutschland GmbH
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2021-07-01
DC.identifier	https://doi.org/10.1007/s10067-021-05609-7
DC.subject	ANSWER cohort
	Baricitinib
	Drug retention
	Rheumatoid arthritis
	Sarilumab
	Tofacitinib
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s10067-021-05609-7
DC.description	Ebina K., Hirano T., Maeda Y., et al. Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study. Clinical Rheumatology 40, 2673 (2021)
DCTERMS.abstract	Objectives: The aim of this multicenter, retrospective study was to clarify the retention rates of sarilumab (SAR), baricitinib (BAR), and tofacitinib (TOF) in patients with rheumatoid arthritis (RA). Methods: Patients treated with either SAR (n = 62), BAR (n = 166), or TOF (n = 185) (females, 80.9%; age, 61.0 years; disease duration, 11.1 years; rheumatoid factor positivity, 84.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate, 4.3; concomitant prednisolone dose, 5.3 mg/day [47.0%] and methotrexate dose, 8.8 mg/week [58.4%]; biologics- or Janus kinase inhibitors-switched cases 78.4%) were included. The reasons for drug discontinuation were classified into 4 major categories (lack of effectiveness, toxic adverse events, non-toxic reasons, and remission) by each attending physician. The drug retention rate was estimated at 18 months using the Kaplan–Meier method and adjusted for potential confounders by Cox proportional hazards modeling. Results: The discontinuation rates of SAR, BAR, and TOF for the corresponding reasons were as follows, respectively: lack of effectiveness (15.7%, 15.6%, and 21.5%; P = 0.84), toxic adverse events (15.8%, 12.1%, and 12.3%; P = 0.35), non-toxic reasons (10.9%, 7.7%, and 6.8%; P = 0.35), and remission (0.0%, 2.8%, and 0.0%; P = 1.0). The overall retention rates excluding non-toxic reasons and remission were as follows: 68.8% for SAR, 72.5% for BAR, and 66.7% for TOF (P = 0.54). Conclusions: After adjustment by potent confounders, SAR, BAR, and TOF showed similar discontinuation rates due to lack of effectiveness and toxic adverse events.Key Points• This is the first retrospective multicenter study that aimed to clarify the retention rates and reasons for discontinuation of SAR, BAR, and TOF in patients with RA.
DC.rights	© 2021, International League of Associations for Rheumatology (ILAR).
DC.format	93248
citation_title	Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
citation_author	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Onishi, Akira
	Jinno, Sadao
	Hara, Ryota
	Son, Yonsu
	Amuro, Hideki
	Takeuchi, Tohru
	Yoshikawa, Ayaka
	Katayama, Masaki
	Yamamoto, Keiichi
	Hirao, Makoto
	Okita, Yasutaka
	Kumanogoh, Atsushi
	Nakata, Ken
citation_publisher	Springer Science and Business Media Deutschland GmbH
citation_language	English
citation_date	2021-07-01
citation_journal_title	Clinical Rheumatology
citation_volume	40
citation_issue	7
citation_firstpage	2673
citation_lastpage	2680
citation_doi	https://doi.org/10.1007/s10067-021-05609-7
citation_public_url	https://hdl.handle.net/11094/93248

Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study

Link to primary information

Item Information

Show details